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Abstract 
Aims: The ADIPOQ gene encodes the protein adiponectin and decreased circulating adiponectin 
levels have been observed in cardiovascular disease.  We investigated the role of the ADIPOQ gene 
single nucleotide polymorphisms (SNPs) A-11426G, G-11391A, C-11377G and T45G with plasma 
adiponectin levels and common carotid artery intima media thickness (IMT) in a cohort of healthy 
subjects participating in the RISC (Relationship between Insulin Sensitivity and Cardiovascular 
disease) study.   
Method and Results:  Anthropometric and metabolic assessment and B-mode ultrasound of the 
carotid IMT was measured in 1306 subjects (589 men; 717 women, mean (SE) age 43.8 (0.2) years, 
BMI 25.5 (0.1) kg/m2) recruited from 19 centres in 14 European countries. Carriers of the -11426G 
allele and homozygous carriers of the -11391G allele had significantly lower plasma adiponectin 
levels.  These relationships remained significant after adjusting for age, sex, recruitment centre and 
BMI.  Carriers of SNP -11377G allele had significantly greater IMT values compared to C allele 
homozygotes (geometric mean [interquartile range], 601 [543-665] vs. 590 [537-647] µm, P=0.021). 
This relationship became stronger after correcting for key covariates, including plasma adiponectin 
levels (P=0.011).   
Conclusions:  Variation within the ADIPOQ gene promoter is directly associated with carotid IMT in 
healthy subjects and is independent of circulating adiponectin levels.   
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Introduction 
A susceptibility locus for type 2 diabetes and the metabolic syndrome has been mapped to 
chromosome 3q271.  The ADIPOQ gene is located at position 3q27 and encodes the protein 
adiponectin.  Decreased circulating adiponectin levels have been observed in cardiovascular 
disease (CVD), obesity and type 2 diabetes compared to healthy controls2,3.   Adiponectin has 
been shown to suppress the transformation of macrophages into foam cells4 and is detected in 
catheter injured vessels but not in intact vessels5.  Low adiponectin levels are associated with 
endothelial dysfunction6 and increased carotid intima media thickness (IMT)7, while higher 
plasma levels have been associated with a lower risk of myocardial infarction3.   
A number of SNPs in the ADIPOQ gene have been described8, 9.  The SNP 45G allele has been 
associated with coronary artery disease (CAD)10 and abdominal obesity11 in French Caucasians 
and with type 2 diabetes in Japanese populations12.  A common haplotype of SNPs G-11391A 
and C-11377G in the proximal promoter region of the ADIPOQ gene has been associated with 
circulating adiponectin levels and type 2 diabetes in French Caucasians8.  Recent studies have 
shown SNP A-11426G to be associated with fasting plasma glucose levels and type 2 diabetes9, 
13
 and SNP C-11377G with coronary stenosis and vascular events14.  Therefore it is evident that 
SNPs in the ADIPOQ gene may be associated with CVD and type 2 diabetes.  However, most 
studies have investigated the relationships between ADIPOQ and adiponectin levels in disease 
states and there is limited work investigating the role of these SNPs and CVD risk in healthy 
individuals.   
The aim of this study was to explore the relationships amongst ADIPOQ gene common variants 
(SNPs A-11426G, G-11391A, C-11377G and T45G) and carotid IMT and plasma adiponectin 
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levels in healthy subjects participating in the RISC (Relationship between Insulin Sensitivity and 
Cardiovascular disease) study. 
 
Subjects and methods 
Subjects 
The RISC study is a prospective, observational, multi-centre cohort study designed to 
establish: (1) whether insulin resistance predicts deterioration of CVD risk markers, 
diabetes, obesity, atherosclerosis and CVD; (2) to determine the genetic and environmental 
contributions to insulin resistance and CVD; (3) to develop a method to identify insulin 
resistant individuals in clinical practice15.  The study recruitment methods and 
inclusion/exclusion criteria have been previously described15, 16.  Briefly, healthy Caucasian men 
and women, aged between 30-60 years, were recruited from 19 centres in 14 European countries. 
The baseline data collection began in June 2002 and was completed in July 2005.  Each 
recruitment centre obtained local ethics committee approval and participants gave 
separate written consent for the study and the collection of DNA.   In total, 1566 
participants were initially screened and excluded (n = 190) if: systolic and diastolic blood 
pressure (BP) was ≥140/90 mmHg; fasting plasma glucose ≥7.0 mmol/l; 2h plasma glucose 
≥11.1 mmol/l; total cholesterol ≥7.8 mmol/l; triglycerides ≥4.6 mmol/l or had ECG 
abnormalities and carotid artery plaques.  A further 50 participants dropped out or did not 
show for appointments.  The final study number was 1326, of which 1311 consented to 
providing blood samples for DNA analysis.  The analysis presented in this paper is based on 
1306 subjects (589 men, 717 women) who had passed the eligibility criteria and had complete 
data on ADIPOQ genotypes.  
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Biological and lifestyle measurements   
Height was measured on a stadiometer and body weight and fat free mass was measured on a 
TANITA bioimpedance (Tanita International Division, UK).  Waist circumference was measured 
by tape according to a standardised written protocol.  Sitting blood pressure was measured 
(OMRON 705 cp, OMRON Healthcare Europe, The Netherlands) three times over 10 min and 
the median value was used in statistical analysis.  Smoking status was self-reported by study 
questionnaire.  Fasting blood samples were taken before and 30, 60, 90 and 120 min into the oral 
glucose tolerance test (OGTT), together with samples for central analysis of routine blood 
chemistry and for DNA extraction.  Blood collected during the studies was separated into plasma 
and serum, aliquoted and stored at –20°C for glucose and –80°C for lipids.  Serum aliquots were 
also stored at –80°C for insulin determination.  Samples were transported on dry ice at pre- 
arranged intervals to central laboratories.  Plasma insulin was measured by a specific 
chemiluminescence assay15.  On a separate day within one month of the OGTT, a euglycaemic 
hyperinsulinaemic clamp was performed in all subjects.  Exogenous insulin was administered as 
a primed-continuous infusion at a rate of 240 pmol.min-1.m-2 simultaneously with a variable 20% 
dextrose infusion adjusted every 5-10 min to maintain plasma glucose level within 0.8 mmol/l 
(±15%) of the target glucose level (4.5-5.5 mmol/l).  The clamp procedure was standardised 
across centers with the use of a demonstration video and ad hoc operating instructions; the raw 
data from each clamp study were immediately transferred to the coordinating centre where they 
underwent quality control scrutiny according to pre-set criteria.  Insulin sensitivity was expressed 
as the ratio of the M value17 averaged over the final 40 min of the 2-hour clamp and normalised 
by the fat-free mass to the mean plasma insulin concentration measured during the same interval 
(M/I, in units of µmol.min-1.kgffm-1.mM-1). LDL cholesterol concentration was calculated by the 
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Friedewald formula18.  Genomic DNA was extracted using a Nucleon BACC2 kit (Tepnel Life 
Sciences Plc, Manchester, UK).  
  
Plasma adiponectin measurements 
Plasma adiponectin was determined as previously described by a novel in-house time-resolved 
immunofluorometric assay (TR-IFMA) based on two antibodies and recombinant human 
adiponectin (R & D Systems, Abingdon, UK)19.  The adiponectin molecule is known to form a wide 
range of polymers, of which the predominant polymers include trimers, hexamers and highly 
congregated multimers20.  Previous experiments have demonstrated that both antibodies used are 
able to detect several adiponectin polymers in serum, including the major three molecular forms. All 
standards and unknown samples were analysed in duplicate, with the exception of non-specific 
binding (NSB), which was analyzed in quadruplicate.  The intra-assay coefficient of variation (CV) 
was <5 % and the inter-assay CV was <10 %. 
 
Carotid IMT measurements 
The carotid ultrasound method used a standardized scanning protocol common to all recruiting 
centres, and central reading of ultrasound studies15.  In each centre, certified trained technicians 
performed high-resolution B-mode ultrasound of extracranial carotid arteries bilaterally, 
according to previously described scanning protocol21.  The whole imaging procedure was 
recorded on S-VHS tapes and read in a centralized reading centre (Pisa) by a single reader (M.K) 
blinded to clinical data, using a high resolution video recorder (Panasonic AG- MD830) coupled 
with a computer-driven image analysis system developed by the Institute of Clinical Physiology, 
CNR, Pisa Italy.  For the purpose of this study, IMT of the near and far wall of the right and left 
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CCA were measured in digitized end-diastolic frames, ~10 mm proximal to bifurcation.  The 
measurements were performed in 5 measurement points for each wall, and the mean near- and 
far-wall IMTs were calculated by averaging the measurement points.  Mean CCA IMT used in 
the statistical analyses was calculated as the overall mean of all available CCA walls (up to four). 
Both near- and far-wall IMT were measured in this study as it was previously demonstrated that 
only far-wall measurement had significantly lower association with cardiovascular outcomes 
than the combined near- and far-wall measurements22.  The intra- and inter-observer variability 
of CCA IMT measurements were tested in 100 subjects, and were 4.1 and 6.2%, respectively.  
 
ADIPOQ SNP genotyping 
SNP T45G 
A matrix-assisted laser desorption/ ionisation time-of-flight (MALDI-TOF) mass spectrometry 
(Sequenom MassARRAY, San Diego, CA, USA) method was used to genotype SNP T45G.  The 
primers were designed using the Sequenom MassARRAY Assay design program version 2.0.4 
(Sequenom, San Diego, CA, USA).  The PCR primer sequences were as follows: forward primer 
5’AGTGCACATGTGGATTCCAG 3’, reverse primer 5’ CCTTGAGTCGTGGTTTCCTG-3’.  
A 5µl PCR reaction was set up using 2 ng DNA, 1.25 × HotStar Taq PCR buffer, 3.5 mM MgCl2 
per reaction, 200 µM each dNTP, 100 nM each of forward and reverse primers and 0.15 U 
HotStar Taq polymerase (Qiagen, UK).  PCR amplification was performed in 384 well PCR 
plates and cycling conditions were as follows: 95°C for 15 min and 35 cycles of 95°C for 20 s, 
58°C for 30 s, 72°C for 1 min, followed by a final extension step of 72°C for 3 min.  Following 
this a primer extension reaction was performed using the mass extend primer 5-
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CTATTAGCTCTGCCCGG-3 and samples were then prepared according to the manufacturers 
methods (Sequenom, San Diego, CA, USA) for genotyping using MALDI-TOF.    
 
SNPs A-11426G, G-11391A, C-11377G 
The ADIPOQ promoter SNPs were genotyped using a TaqMan® allelic discrimination assay 
(Applied Biosystems, Warrington, UK).  Primers and probes were designed using the Assay by 
Design Service (Applied Biosciences, Warrington, UK).  For each SNP, a 25 µl PCR reaction 
was set up with 10 ng of genomic DNA, 1x TaqMan® universal PCR MasterMix with 
AmpErase® UNG and 1 x primer and probes assay mix.  Samples were amplified on a GeneAmp 
9700 PCR machine (Applied Biosciences, Warrington, UK).  PCR cycling conditions were as 
follows: 50ºC for 2 min followed by 95ºC for 10 min, then 40 cycles of 92ºC for 0.15 sec, 60ºC 
for 1 min.  Following PCR, an allelic discrimination assay was performed on an ABI Prism 7000 
sequence detection system (Applied Biosystems, Warrington, UK).                    
 
Quality control 
Of the genotyped samples, 5% were duplicates and there was at least 1 negative control per 96 
well DNA plate.  The accuracy of the genotyping was determined by the genotype concordance 
between duplicate samples.  We obtained a 100% concordance between the genotyped duplicate 
samples for each of the SNPs.  The genotyping success rate for each of the SNPs was >98 %. 
 
Statistical analysis 
All analysis was performed using SPSS version 13 (SPSS Inc., Chicago, IL, USA) and Minitab 
version 14 (Minitab Inc, USA).  The Haploview program 
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http://www.broad.mit.edu/mpg/haploview/ version 3.223 was used to assess linkage 
disequilibrium (LD) between the genotyped SNPs.  Data are reported as mean ± SD.  Skewed 
variables (plasma adiponectin, carotid IMT, fasting serum insulin, M/I value, fasting 
triglycerides) were log transformed for analysis and are presented as geometric means and the 
interquartile range [25th – 75th quartile]. The Pearson’s correlation coefficient was determined for 
the associations of biological variables with log transformed plasma adiponectin levels.  Single 
SNP effects with continuous variables were analysed using linear regression using 3 models; 
these were the additive (common allele homozygotes coded as 1, heterozygotes as 2 and 
recessive allele homozygotes as 3), dominant (common allele homozygotes coded as 1 and 
heterozygotes and recessive allele homozygotes as 2) and recessive (common allele 
homozygotes and heterozygotes coded as 1 and recessive allele homozygotes as 2) models.  
General linear Model (GLM) analysis was performed to test for associations between SNP 
genotypes and continuous variables (log carotid IMT and log adiponectin) after adjusting 
for confounding variables (sex, BMI, recruitment centre and age).  Normality was assessed 
by plotting the residuals.  For significant associations, further adjustments were made in 
the GLM analysis for other known CVD risk factors (HDL-, LDL-, total cholesterol, 
triglycerides, blood pressure, fasting insulin, M/I, fasting and 2 hr glucose, waist 
circumference, smoking and adiponectin levels). Two-tailed P values <0.05 were considered 
significant, however allowance for multiple testing was done in the interpretation of the 
significant results for testing the 4 ADIPOQ SNP’s (a global significance level of 0.05 means 
a single test significance level of 0.0127) in the GLM analysis.  ADIPOQ gene promoter 
haplotype frequencies were estimated and the likely pair of haplotypes (diplotypes) were 
reconstructed using the PHASE 2.1 software24.  We performed 10000 iterations of each run to 
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produce reliable probability estimates.  Rare diplotypes with population frequencies less than 
0.01 were omitted.  
 
Results 
Characteristics and biological variables of the study cohort  
The study cohort consists of 1306 subjects (589 men and 717 women) aged 43.8 ± 8.3 yrs (mean 
± SD), with a mean BMI of 25.5 ± 4.0 kg/m2.  The clinical and metabolic characteristics of 
the study population are shown separately for men and women in Table 1.  Table 2 shows 
the correlation between biological variables with plasma adiponectin levels in men and women.  
All listed variables were significantly correlated (P values <0.05) with plasma adiponectin except 
for LDL-cholesterol and systolic blood pressure in men.  However, there was no significant 
correlation of carotid IMT with plasma adiponectin in both men (r = -0.05) and women (r = -
0.05). 
 
ADIPOQ genotype and haplotype frequencies       
All genotyped SNPs were in Hardy-Weinberg equilibrium and common with minor allele 
frequencies >0.05. There were no significant differences in the genotype or allele frequencies for 
the SNPs between subjects that made up the North and South European recruitment centres (P 
values >0.05); therefore recruitment centres were combined for subsequent analysis.   Table 3 
shows detailed information for each SNP and the allele and genotype frequencies.  There was 
strong LD (D’ > 0.8) between the 3 promoter SNPs and weak associations between these 
promoter SNPs and SNP T45G in exon 2 of the ADIPOQ gene.  The estimated haplotype 
frequencies consisting of the 3 promoter SNPs A-11426G, G-11391A, C-11377G were 59.5% 
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for AGC, 23.9% for AGG, 9.0% for GGC and 7.4% for AAC.  Haplotype frequencies were 
similar to those previously reported in French and Swedish Caucasians8, 13.   
 
Relationships between ADIPOQ SNPs and plasma adiponectin levels and carotid IMT 
By linear regression analysis, SNPs A-11426G and G-11391A were significantly associated with 
plasma adiponectin levels, and SNP C-11377G was significantly associated with carotid IMT in 
the dominant model (Table 4).  Homozygous carriers of the -11391G allele had significantly 
lower plasma adiponectin levels compared to A allele carriers (geometric mean [interquartile 
range], 7.4 [5.4 - 10.0] vs. 9.1 [6.9 - 12.2] mg/l, P <0.0001).  Plasma adiponectin levels remained 
significantly lower after adjusting for age, sex, BMI and recruitment centre (P<0.0001).  
Similarly, for SNP A-11426G, carriers of the G allele had significantly lower plasma adiponectin 
levels compared to A allele homozygotes before (P = 0.015) and after adjustment (P = 0.005) for 
the same covariates.  The diplotype containing the haplotype -11426G, -11391G, -11377C was 
significantly associated with adiponectin levels.  Diplotypes AGC/GGC and GGC/GGC were 
significantly associated with lower plasma adiponectin levels (Table 5) compared to all other 
diplotypes before (P = 0.003) and after adjustment for sex, age, BMI and recruitment centre 
(P = 0.010).  
Only SNP C-11377G was associated with carotid IMT.  Carriers of the G allele had significantly 
greater carotid IMT values compared to C allele homozygotes (geometric mean [interquartile 
range], 601 [543 - 665] vs. 590 [537 - 647] µm, P = 0.021) (Table 4).  This difference remained 
after adjusting for age, sex, recruitment centre, BMI, as well as plasma adiponectin levels and 
other determinants of CVD risk (Table 4: GLM model 2; P = 0.011).  The results remain 
significant at a global 5% significance level when allowance is made for testing the 4 SNPS.  
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The diplotype containing the haplotype -11426A -11426G -11377G was significantly associated 
with carotid IMT values (Table 5).  Diplotypes AGC/AGG and AGG/AGG were associated with 
higher carotid IMT values compared to all other diplotypes (604 [543 - 665] vs. 592 [540 - 650] 
µm, P = 0.013).  This difference remained significant after correcting for key determinants 
(Table 5: GLM model 2; P = 0.003).  There was no association between SNP T45G and 
adiponectin levels and carotid IMT, however the G allele was associated with increased waist 
circumference (TT vs. TG + GG, 87 ± 0.2 vs. 90 ± 1.5, P = 0.02) after adjustment for age, sex, 
recruitment centre and BMI.   
 
Discussion 
The intriguing observation of our study is that variation in the ADIPOQ gene promoter is directly 
associated with common carotid artery IMT in healthy subjects.  Specifically, individuals with 
the G allele of the C-11377G SNP had significantly higher carotid IMT values compared to C 
allele homozygotes.  This relationship was stronger after correction for key covariates, including 
plasma adiponectin levels.  Our findings are supported by Hoefle et al. (2007)14, who recently 
reported an association between SNP -11377 and coronary angiography determined CAD in a 
prospective study of 402 men.  The SNP -11377 G allele was significantly associated with 
increased coronary stenosis and future vascular events independently of serum adiponectin levels 
and traditional CVD risk factors.    
How might variation in the ADIPOQ gene directly influence carotid IMT?  Clearly, our study 
does not allow us to address this directly, but it is interesting to note that a recent study reported 
that the ADIPOQ gene is expressed in vascular tissue25.  Moreover, ACE inhibitor therapy given 
to type 2 diabetic patients resulted in a 2-fold increase in the vascular expression of the ADIPOQ 
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gene and was associated with an improvement in endothelial function25.  This led the authors to 
speculate that adiponectin generated locally within the vasculature might directly influence 
endothelial function.  This is supported by the observation that globular adiponectin applied to 
cultured vascular endothelial cells increased both the expression and the activity of eNOS26. The 
circulating serum/ plasma levels of adiponectin may not reflect the actual amount of adiponectin 
present at the tissue level, for example the concentration in the sub-endothelial space where the 
anti-atherogenic targets for adiponectin are located27, 28.  Therefore further in vitro studies are 
needed to explore whether variation in the ADIPOQ gene in vascular tissue affects local 
adiponectin expression, endothelial function and ultimately CVD risk.  Although SNP -11377 
was in strong LD with the other promoter SNPs, only the haplotype containing the  -11377 G 
allele was associated with increased carotid IMT.  It may be that SNP -11377 is in LD with 
another nearby functional variant, which directly affects the expression of adiponectin in 
vascular tissue.  
Of the other promoter SNPs, the A-11426G and G-11391A and the haplotype containing the  
-11426 G allele and -11391 G allele was significantly associated with lower plasma adiponectin 
levels, before and after covariate correction.  The SNP -11391A allele has been consistently 
reported associated with higher adiponectin levels in European populations8, 11 and increased in 
vitro transcriptional activity29.  Putative binding sites for transcriptional factors have not been 
found in the promoter region of the ADIPOQ gene where SNPs -11391 and -11377 lie, however 
between these two SNPs and adjacent to the position of the -11377 SNP a nucleotide sequence 
which is similar to an enhancer element sequence in the epidermal growth factor receptor gene 
has been reported8.  
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While there was a strong association between the A-11426G and G-11391A SNPs and 
circulating adiponectin levels, there was, however, no association between these SNPs and 
carotid IMT.  Furthermore, plasma adiponectin levels were not an independent predictor of 
carotid IMT in our study after adjustment for the usual covariates and CVD determinants (data 
not shown).  The majority of studies investigating ADIPOQ gene SNPs and adiponectin levels 
have been reported in disease states, especially in subjects with type 2 diabetes and CVD.  Our 
study is a large healthy cohort and therefore we are able to dissect out relationships independent 
of the potentially confounding secondary effects of the disease. However, it is important to note 
that our study is cross-sectional; on the other hand, the RISC project is a longitudinal study of 
CVD risk and so we will, in time, be able to investigate the relationship between circulating 
adiponectin levels and carotid IMT progression.  
A previous study reported an association of SNP T45G with CAD in patients with type 2 
diabetes, independent of other CVD risk factors10.  We were unable to show a relationship 
between the G allele and carotid IMT in healthy subjects, but we did replicate the reported 
association between the SNP 45G allele and increased waist circumference11.   
The RISC study is a multi-center European study and allows us to investigate a large and well-
characterized healthy population.  However, due to the high number of recruiting centers, 
different operators and ultrasound scanners have been used for the carotid studies. To restrict this 
limitation, all ultrasound technicians were trained and certified in the ultrasound-reading center, 
the carotid imaging procedure was performed according to a standardized protocol21 and a single 
reader processed and analysed the carotid images. All analyses were center-adjusted.  We 
acknowledge that the difference in carotid IMT between the SNP -11377 genotype groups was 
small in clinical terms, however our results are supported by the study of Hoefle et al., (2007) 
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who reported an association of SNP -11377 with coronary stenosis and vascular events in CAD 
subjects14.  
In conclusion, variation in the ADIPOQ gene promoter was associated with carotid IMT in a 
large cohort of healthy subjects, and this was independent of plasma adiponectin levels and other 
determinants of CVD risk.  While our observation will require further replication, it does support 
the concept that variation in the ADIPOQ gene directly influences carotid IMT and CVD risk. 
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Table 1:  Shows the clinical and metabolic characteristics of males and females in the RISC 
study cohort 
Data presented as means ± SD, †geometric means [25th - 75th quartile]. M/I insulin sensitivity 
assessed by euglycaemic clamp. IMT intima media thickness. 
  
 Male Female 
n 589 717 
Age (years) 43 ± 8 44 ± 8 
BMI (kg/m2) 26.4 ± 3.5 24.9 ± 4.3 
Waist circumference (cm) 93 ± 10 81 ± 12 
†Fasting insulin (pmol/l) 32.1 [22.0 - 46.0] 29.3 [20.0 - 40.0] 
†M/I (µmol/min-1/kgffm-1/nM-1) 109 [83 - 154] 140 [110 - 193] 
Fasting glucose (mmol/l) 5.3 ± 0.8 4.9 ± 0.6 
2 hr glucose (mmol/l) 5.7 ± 1.6 5.8 ± 1.5 
†Triglycerides (mmol/l) 1.1 [0.8 - 1.5] 0.9 [0.6 - 1.1] 
Cholesterol (mmol/l) 4.9 ± 0.9 4.8 ± 0.9 
HDL – cholesterol (mmol/l) 1.2 ± 0.3 1.6 ± 0.4 
LDL – cholesterol (mmol/l) 3.1 ± 0.8 2.8 ± 0.8 
Systolic BP (mmHg) 122 ± 10 114 ± 13 
Diastolic BP (mmHg) 76 ± 7 73 ± 8 
†Carotid IMT (µm) 612 [553 - 670] 581 [525 - 640] 
†Plasma adiponectin (mg/l) 6.1 [4.8 - 7.9] 9.2 [7.3 - 12.2] 
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Table 2:  Shows the correlation coefficients between plasma adiponectin with biological 
variables in RISC study subjects 
P values <0.05 considered significant, †log transformed values used in the analysis, M/I insulin 
sensitivity assessed by euglycaemic clamp. IMT intima media thickness. 
 
†Plasma adiponectin (mg/l) 
 Male P value Female P value 
n 589  717  
Age (years) 0.08 0.039 0.09 0.014 
BMI (kg/m2) -0.17 <0.0001 -0.28 <0.0001 
Waist circumference (cm) -0.15 <0.0001 -0.34 <0.0001 
†Fasting insulin (pmol/l) -0.27 <0.0001 -0.38 <0.0001 
†M/I (µmol/min-1/kgffm-1/nM-1) 0.31 <0.0001 0.31 <0.0001 
Fasting glucose (mmol/l) -0.10 0.021 -0.16 <0.0001 
2 hr glucose (mmol/l) -0.21 <0.0001 -0.19 <0.0001 
†Triglycerides (mmol/l) -0.27 <0.0001 -0.29 <0.0001 
HDL – cholesterol (mmol/l) 0.38 <0.0001 0.41 <0.0001 
LDL – cholesterol (mmol/l) -0.07 0.075 -0.11 0.003 
Systolic BP (mmHg) -0.02 0.527 -0.12 0.002 
Diastolic BP (mmHg) -0.08 0.037 -0.11 0.003 
†Carotid IMT (µm) -0.05 0.257 -0.05 0.258 
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Table 3: ADIPOQ SNPs, genotypes and allele frequencies (%) in the RISC study population 
   Allele frequencies (n) 
SNP (*dbSNP ID number) n Genotype frequencies (n) Allele 1  Allele 2 
A-11426G (rs16861194) 1292 
AA 
82.6 (1067) 
AG 
16.1 (208) 
GG 
1.3 (17) 
A 
90.6 (2342) 
G 
9.4 (242) 
G-11391A (rs17300539) 1300 
GG 
85.3 (1109) 
GA 
14.1 (183) 
AA 
0.6 (8) 
G  
92.3 (2401) 
A  
7.7 (199) 
C-11377G (rs266729) 1300 
CC 
56.2 (730) 
CG 
38.8 (505) 
GG 
5.0 (65) 
C  
75.6 (1965) 
G  
24.4 (635) 
T45G (rs2241766) 1306 
TT 
78.1 (1020) 
TG 
20.5 (268) 
GG 
1.4 (18) 
T  
88.4 (2308) 
G 
 11.6 (304) 
*dbSNP, http://www.ncbi.nlm.nih.gov/SNP/
  
26
Table 4: Relationship between ADIPOQ gene SNP genotypes and adiponectin and carotid IMT.  
SNPs/ genotypes *Plasma adiponectin (mg/l) *Carotid IMT (µm) 
A-11426G   
AA 7.7 [5.6 - 10.5] 596 [540 - 655] 
AG + GG 7.2 [5.4 - 9.6] 598 [548 - 652] 
P value 0.015 0.676 
†GLM Model 1 P value 0.005 0.428 
G-11391A   
GG 7.4 [5.4 - 10.0] 596 [540 - 655] 
GA + AA 9.1 [6.9 -12.2] 590 [534 - 653] 
P value <0.0001 0.473 
†GLM Model 1 P value <0.0001 0.917 
C-11377G   
CC 7.7 [5.7 - 10.2] 590 [537 - 647] 
CG + GG 7.6 [5.4 - 10.5] 601 [543 - 665] 
P value 0.669 0.021 
†GLM Model 1 P value 0.273 0.044 
‡GLM model 2 P value - 0.011 
T45G   
TT 7.7 [5.6 - 10.3] 594 [540 - 653] 
TG + GG 7.5 [5.4 - 10.5] 596 [539 - 653] 
P value 0.588 0.838 
†GLM Model 1 P value 0.638 0.999 
*Geometric mean [25th – 75th quartile] presented. P <0.05 considered significant. IMT intima media 
thickness. †P value after adjustment for age, sex, BMI and recruitment centre.  ‡P value after adjustment 
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for other CVD risk factors (HDL-, LDL- and total cholesterol, serum triglycerides, systolic and diastolic 
BP, fasting insulin, insulin sensitivity assessed by the euglycaemic clamp, fasting and 2hr plasma 
glucose, waist circumference, smoking status) as well as age, sex, BMI, recruitment centre and 
adiponectin levels. 
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Table 5: Relationship between ADIPOQ promoter SNP haplotypes and adiponectin and carotid IMT. 
ACDC promoter SNP diplotypes  
(A-11426G G-11391A C-11377G) 
n *Plasma adiponectin (mg/l) *Carotid IMT (µm) 
 
   
AGC/GGC and GGC/GGC 145 6.9 [5.2 - 8.7] 589 [548 - 650] 
All other diplotypes 1153 7.7 [5.6 - 10.5] 596 [540 - 655] 
P value - 0.003 0.422 
†GLM Model 1 P value 
 
0.010 0.185 
 
   
AGC/AGG and AGG/AGG 457 7.4 [5.3 - 10.0] 604 [543 - 665] 
All other diplotypes 841 7.7 [5.7 - 10.2] 592 [540 - 650] 
P value - 0.089 0.013 
†GLM Model 1 P value  0.102 0.027 
‡GLM model 2 P value  - 0.003 
 
*Geometric means [25th – 75th quartile] presented. P <0.05 considered significant. IMT intima media 
thickness. †P value after adjustment for age, sex, BMI and recruitment centre.  ‡P value after adjustment 
for other CVD risk factors (HDL-, LDL- and total cholesterol, serum triglycerides, systolic and diastolic 
BP, fasting insulin, insulin sensitivity assessed by euglycaemic clamp, fasting and 2hr plasma glucose, 
waist circumference, smoking status) as well as age, sex, BMI, recruitment centre and adiponectin levels. 
 
 
 
